Results 81 to 90 of about 10,758 (225)

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Genome Medicine, 2019
We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry, and immunohistochemistry data.
Francesca Finotello, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, Zuzana Loncova, Wilfried Posch, Doris Wilflingseder, Sieghart Sopper, Marieke Ijsselsteijn, Thomas P. Brouwer, Douglas Johnson, Yaomin Xu, Yu Wang, Melinda E. Sanders, Monica V. Estrada, Paula Ericsson-Gonzalez, Pornpimol Charoentong, Justin Balko, Noel Filipe da Cunha Carvalho de Miranda, Zlatko Trajanoski   +22 more
doaj   +1 more source

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Advanced Healthcare Materials, EarlyView.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj, Xilal Y. Rima, Kim T. Nguyen, Courtney Culkins, Nana Boateng, Jacob Doon‐Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, Ajeet Pal Singh, Dharti Shantaram, Anastasiia Amari, Mangesh D. Hade, Nicholas R. Merriam, Zachary D. Schultz, Scott Q. Harper, Nizar Y. Saad, Setty M. Magaña, Willa A. Hsueh, Rachel E. Kopec, Blaise R. Kimmel, Andre F. Palmer, Eduardo Reátegui   +23 more
wiley   +1 more source

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma

Case Reports in Dermatology, 2020
Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors.
Marcos Oro-Ayude, Hae Jin Suh-Oh, Victor Sacristán-Santos, Patricia Vázquez-Bartolomé, Ángeles Flórez   +4 more
doaj   +1 more source

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden

Advanced Healthcare Materials, EarlyView.
Nanoemulsion delivery of a TLR7 agonist enhances safety and promotes colocalization with Leishmania‐infected macrophages in skin lesions, enabling a ∼2‐log reduction in parasite burden. However, tissue‐level constraints and TLR‐driven regulatory feedback generate a mixed immune response that limits complete parasite clearance.
Carmen Palomino‐Cano, M. Carmen Mera‐Delgado, Esther Moreno, Esther Larrea, Lecnia Aguirre, Jonathan Miguel Zanatta, Sónia Barros‐Carvalho, Iola F. Duarte, Ricardo Silvestre, Juan M. Irache, Javier Carrión, Socorro Espuelas   +11 more
wiley   +1 more source

If Plan A Does Not Work: The CD47 Ectodomain as a Target for Immune Tolerance

Cells
Cell surface immune checkpoint receptors are objects for therapeutic intervention to stimulate immune cell attack of cancers. Interference between the checking ectodomain (ECD) and the natural ligand lowers constitutive restraints exerted on immune cells.
Enrique Montero, Jeffrey S. Isenberg
doaj   +1 more source

Trial watch: TLR3 agonists in cancer therapy

OncoImmunology, 2020
Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli   +4 more
doaj   +1 more source

Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy

Advanced Materials, EarlyView.
Co‐encapsulation of p53 mRNA and the small molecule ciclopirox within a lipid nanoparticle yields an all‐in‐one chemoimmunotherapy for oral squamous cell carcinoma. The platform engages caspase‐driven apoptosis in cancer cells while repolarizing tumor‐associated macrophages, achieving tumor reduction in both p53‐susceptible and p53‐resistant models and
Marshall S. Padilla, Jacqueline J. Li, Qunzhou Zhang, Korey Patwari, Shihong Shi, Hannah M. Yamagata, Ryann A. Joseph, Briyanna N. Hymms, Sridatta V. Teerdhala, Emily Fitzgerald, Ori Z. Chalom, Kushol Gupta, Mohamad‐Gabriel Alameh, Drew Weissman, Anh D. Le, Michael J. Mitchell   +15 more
wiley   +1 more source

Reprogramming the Immunosuppressive Microenvironment in Triple‐Negative Breast Cancer via FAP‐Targeted Nanoprobes for Multimodal Imaging and Photothermal Therapy

Advanced Materials, EarlyView.
Targeting cancer‐associated fibroblasts (CAFs) with fibroblast activation protein (FAP)‐directed nanoprobes for multimodal imaging and photothermal remodeling of the immunosuppressive microenvironment to enhance immunotherapy in triple‐negative breast cancer (TNBC).
Ling Zhan, Yanhong Chen, Jingjing Hu, Chunting Wang, Huanhuan Liu, Defan Yao, Dengbin Wang   +6 more
wiley   +1 more source

Trial watch: IDO inhibitors in cancer therapy

OncoImmunology, 2020
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first, rate-limiting step of the so-called “kynurenine pathway”, which converts the essential amino acid L-tryptophan (Trp) into the immunosuppressive metabolite L-kynurenine (Kyn).
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli   +4 more
doaj   +1 more source

Stromal‐Derived IL‐8 Promotes M2 Macrophage Polarization via the RhoA/MRTF‐A/SRF Transcriptional Axis to Impair CD8+ T Cell Cytotoxicity in Lung Cancer

Advanced Science, EarlyView.
In the recondite pulmonary neoplastic milieu, DESMIN+ cancer‐associated fibroblasts function as the paramount stromal source of IL‐8, precipitating a deleterious immunological metamorphosis by engaging CXCR2 receptors on the myeloid lineage. This paracrine stimulus triggers a mechanotransduction cascade characterized by RhoA‐dependent actin ...
Xuyu Gu, Qiyu Fang, Jia Yu, Ting Yu, Huashan Shi, Kaiqi Jin, Lei Jiang, Wentian Zhang   +7 more
wiley   +1 more source